Alzheimer’s disease

The Behavioral Neurology of Dementia

Volumn 9780521853958, Issue , 2009, Pages 56-73

  Matthews, Brandy R ^a   Miller, Bruce L ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926983462     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511581410.005     Document Type: Chapter

References (215)

1. Morris J. Clinical presentation and course of Alzheimer disease. In Terry R, Katzman R, Bick K, Sisodia S (eds.) Alzheimer Disease. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:11-24.
2. Moller HJ, Graeber MB. The case described by Alois Alzheimer in 1911. Historical and conceptual perspectives based on the clinical record and neurohistological sections. Eur Arch Psychiatry Clin Neurosci 1998;248(3):111-22.
3. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997;11(Suppl 6):135-45.
4. Ferri CP, Prince M, Brayne C et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366 (9503):2112-17.
5. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 2003;26:81-104.
6. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88(9):1337-42.
7. Kukull WA, Ganguli M. Epidemiology of dementia: concepts and overview. Neurol Clin 2000;18(4):923-50.
8. Bachman DL, Wolf PA, Linn R et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology 1992;42(1):115-19.
9. Kokmen E, Beard CM, Offord KP, Kurland LT. Prevalence of medically diagnosed dementia in a defined United States population: Rochester, Minnesota, January 1, 1975. Neurology 1989;39(6):773-6.
10. Miech RA, Breitner JC, Zandi PP et al. Incidence of AD may decline in the early 90s for men, later for women: the Cache County study. Neurology 2002; 58(2):209-18.
11. Ruitenberg A, Ott A, van Swieten JC, Hofman A, Breteler MM. Incidence of dementia: does gender make a difference? Neurobiol Aging 2001;22(4): 575-80.
12. Tang MX, Cross P, Andrews H et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001; 56(1):49-56.
13. Perkins P, Annegers JF, Doody RS et al. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. Neurology 1997;49(1):44-50.
14. Wolfson C, Wolfson DB, Asgharian M et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344(15):1111-16.
15. Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154(7):642-8.
16. Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord 2005;19(4):178-83.
17. Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 2006;20(1):63-72.
18. Mayeux R, Ottman R, Maestre G et al. Synergistic effects of traumatic head injury and apolipoproteinepsilon 4 in patients with Alzheimer’s disease. Neurology 1995;45(Pt 1):555-7.
19. Jordan BD, Relkin NR, Ravdin LD et al. Apolipoprotein E epsilon4 associated with chronic traumatic brain injury in boxing. JAMA 1997;278(2):136-40.
20. Plassman BL, Havlik RJ, Steffens DC et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology 2000;55(8): 1158-66.
21. Guo Z, Cupples LA, Kurz A et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000; 54(6):1316-23.
22. Luchsinger JA, Tang MX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63(7):1187-92.
23. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006;20(4): 298-301.
24. Decarli C. Vascular factors in dementia: an overview. J Neurol Sci 2004;226(1-2):19-23.
25. Breteler MM. Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 2000;21(2):153-60.
26. Kivipelto M, Helkala EL, Hanninen T et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001;56(12):1683-9.
27. Petrovitch H, White LR, Izmirilian G et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging 2000; 21(1):57-62.
28. Wolf H, Julin P, Gertz HJ, Winblad B, Wahlund LO. Intracranial volume in mild cognitive impairment, Alzheimer’s disease and vascular dementia: evidence for brain reserve? Int J Geriatr Psychiatry 2004; 19(10):995-1007.
29. Beeri MS, Davidson M, Silverman JM et al. Relationship between body height and dementia. Am J Geriatr Psychiatry 2005;13(2):116-23.
30. Abbott RD, White LR, Ross GW et al. Height as a marker of childhood development and late-life cognitive function: the Honolulu-Asia Aging Study. Pediatrics 1998;102(Pt 1):602-9.
31. Wilson RS, Scherr PA, Bienias JL et al. Socioeconomic characteristics of the community in childhood and cognition in old age. Exp Aging Res 2005;31(4):393-407.
32. Hall KS, Gao S, Unverzagt FW, Hendrie HC. Low education and childhood rural residence: risk for Alzheimer’s disease in African Americans. Neurology 2000;54(1):95-9.
33. Moceri VM, Kukull WA, Emanuel I, van Belle G, Larson EB. Early-life risk factors and the development of Alzheimer’s disease. Neurology 2000;54(2):415-20.
34. Wilson RS, Scherr PA, Hoganson G et al. Early life socioeconomic status and late life risk of Alzheimer’s disease. Neuroepidemiology 2005;25(1):8-14.
35. Kaplan GA, Turrell G, Lynch JW et al. Childhood socioeconomic position and cognitive function in adulthood. Int J Epidemiol 2001;30(2):256-63.
36. Mortimer JA. Brain reserve and the clinical expression of Alzheimer’s disease. Geriatrics 1997;52(Suppl 2): S50-3.
37. Qiu C, Backman L, Winblad B, Aguero-Torres H, Fratiglioni L. The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol 2001; 58(12):2034-9.
38. Roe C, Xiong C, Miller J, Morris J. Education and Alzheimer disease without dementia: support for the cognitive reserve hypothesis. Neurology 2007; 68(3):223-8.
39. Kittner SJ, White LR, Farmer ME et al. Methodological issues in screening for dementia: the problem of education adjustment. J Chronic Dis 1986;39(3): 163-70.
40. Zhang MY, Katzman R, Salmon D et al. The prevalence of dementia and Alzheimer’s disease in Shanghai, China: impact of age, gender, and education. Ann Neurol 1990;27(4):428-37.
41. Stern Y, Gurland B, Tatemichi TK et al. Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994;271(13):1004-10.
42. Karp A, Kareholt I, Qiu C et al. Relation of education and occupation-based socioeconomic status to incident Alzheimer’s disease. Am J Epidemiol 2004; 159(2):175-83.
43. Stern Y, Albert S, Tang MX, Tsai WY. Rate of memory decline in AD is related to education and occupation: cognitive reserve? Neurology 1999;53(9):1942-7.
44. Stern Y, Habeck C, Moeller J et al. Brain networks associated with cognitive reserve in healthy young and old adults. Cereb Cortex 2005;15(4):394-402.
45. Plassman BL, Welsh KA, Helms M et al. Intelligence and education as predictors of cognitive state in late life: a 50-year follow-up. Neurology 1995;45(8):1446-50.
46. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer’s disease. Lancet Neurol 2004;3(10):579-87.
47. Deng J, Zhou DH, Li J et al. A 2-year follow-up study of alcohol consumption and risk of dementia. Clin Neurol Neurosurg 2006;108(4):378-83.
48. Ruitenberg A, van Swieten JC, Witteman JC et al. Alcohol consumption and risk of dementia: the Rotterdam Study. Lancet 2002;359(9303):281-6.
49. Mukamal KJ, Kuller LH, Fitzpatrick AL et al. Prospective study of alcohol consumption and risk of dementia in older adults. JAMA 2003;289(11): 1405-13.
50. Laitinen MH, Ngandu T, Rovio S et al. Fat intake at midlife and risk of dementia and Alzheimer’s disease: a population-based study. Dement Geriatr Cogn Disord 2006;22(1):99-107.
51. Morris MC, Evans DA, Bienias JL et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003;60(2):194-200.
52. Morris MC, Evans DA, Bienias JL et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60(7):940-6.
53. Rovio S, Kareholt I, Helkala EL et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease. Lancet Neurol 2005; 4(11):705-11.
54. Larson EB, Wang L, Bowen JD et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144(2):73-81.
55. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol 2004; 3(6):343-53.
56. Wilson RS, Bennett DA, Bienias JL et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002;59(12):1910-14.
57. Gatz M. Educating the brain to avoid dementia: can mental exercise prevent Alzheimer disease? PLoS Med 2005;2(1):e7.
58. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115(6): 1449-57.
59. Gatz M, Reynolds CA, Fratiglioni L et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63(2):168-74.
60. Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991;349(6311):704-6.
61. Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995;375 (6534):754-60.
62. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995;269(5226):973-7.
63. Rogaeva EA, Fafel KC, Song YQ et al. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 2001;57(4):621-5.
64. Wisniewski K, Wisniewski H, Wen G. Occurrence of neuropathological changes and dementia of Alzheimer’s disease in Down’s syndrome. Ann Neurol 1985;17:278-82.
65. Evenhuis HM. The natural history of dementia in Down’s syndrome. Arch Neurol 1990;47(3):263-7.
66. Schupf N, Kapell D, Nightingale B et al. Specificity of the fivefold increase in AD in mothers of adults with Down syndrome. Neurology 2001;57(6):979-84.
67. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261(5123):921-3.
68. Poirier J, Davignon J, Bouthillier D et al. Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 1993; 342(8873):697-9.
69. Slooter AJ, Cruts M, Kalmijn S et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55(7):964-8.
70. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278(16): 1349-56.
71. Meyer MR, Tschanz JT, Norton MC et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nat Genet 1998;19(4):321-2.
72. Rogaeva E, Meng Y, Lee JH et al. The neuronal sortilinrelated receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007;39(2):168-77.
73. Scherzer CR, Offe K, Gearing M et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004;61(8):1200-5.
74. Dodson SE, Gearing M, Lippa CF et al. LR11/Sor LA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol 2006;65(9):866-72.
75. Corey-Bloom J. Alzheimer’s Disease. In Miller A (ed.) Continuum: Dementia. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004:29-57.
76. Graeber MB, Mehraein P. Reanalysis of the first case of Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci 1999;249 (Suppl 3):10-13.
77. Haass C, Schlossmacher MG, Hung AY et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature 1992;359(6393):322-5.
78. Blessed G, Tomlinson B, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
79. Bayer TA, Wirths O, Majtenyi K et al. Key factors in Alzheimer’s disease: beta-amyloid precursor protein processing, metabolism and intraneuronal transport. Brain Pathol 2001;11(1):1-11.
80. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6.
81. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron 2004;44(1):181-93.
82. Iqbal K, Alonso Adel C, Chen S et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739(2-3):198-210.
83. Braak E, Griffing K, Arai K et al. Neuropathology of Alzheimer’s disease: what is new since A. Alzheimer. Eur Arch Psychiatry Clin Neurosci 1999;249(Suppl 3): 14-22.
84. Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet 2006;368(9533):387-403.
85. Hyman BT, van Hoesen GW, Damasio AR, Barnes CL. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225(4667): 1168-70.
86. Fuller G, Goodman J. Neurodegenerative disorders. Practical Review of Neuropathology. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001:257-264.
87. Mesulam M, Shaw P, Mash D, Weintraub S. Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann Neurol 2004; 55(6):815-28.
88. Storga D, Vrecko K, Birkmayer JG, Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 1996;203(1):29-32.
89. Reinikainen KJ, Paljarvi L, Huuskonen M et al. A post-mortem study of noradrenergic, serotonergic and GAB Aergic neurons in Alzheimer’s disease. J Neurol Sci 1988;84(1):101-16.
90. Reinikainen KJ, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer’s disease: implications to diagnostics and therapy. J Neurosci Res 1990;27(4):576-86.
91. Keller JN. Age-related neuropathology, cognitive decline, and Alzheimer’s disease. Ageing Res Rev 2006; 5(1):1-13.
92. Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol 1985;42(11):1097-105.
93. Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991; 41(4):479-86.
94. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239-59.
95. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 1997;18(4 Suppl):S1-2.
96. Gorno-Tempini ML, Dronkers NF, Rankin KP et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004; 55(3):335-46.
97. McMonagle P, Deering F, Berliner Y, Kertesz A. The cognitive profile of posterior cortical atrophy. Neurology 2006;66(3):331-8.
98. Lyketsos CG, Lopez O, Jones B et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA 2002;288(12):1475-83.
99. Tatsch MF, Bottino CM, Azevedo D et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006;14(5):438-45.
100. Cummings JL. Alzheimer’s disease. N Engl J Med 2004;351(1):56-67.
101. Ortiz F, Fitten LJ, Cummings JL, Hwang S, Fonseca M. Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2006; 21(4):263-73.
102. Chow TW, Liu CK, Fuh JL et al. Neuropsychiatric symptoms of Alzheimer’s disease differ in Chinese and American patients. Int J Geriatr Psychiatry 2002; 17(1):22-8.
103. Cummings JL, Mega M, Gray K et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14.
104. Tang-Wai DF, Graff-Radford NR, Boeve BF et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology 2004; 63(7):1168-74.
105. Boeve BF, Maraganore DM, Parisi JE et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999;53(4):795-800.
106. Caselli RJ, Stelmach GE, Caviness JN et al. A kinematic study of progressive apraxia with and without dementia. Mov Disord 1999;14(2):276-87.
107. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 1999;56(10):1233-9.
108. Kramer JH, Miller BL. Alzheimer’s disease and its focal variants. Semin Neurol 2000;20(4):447-54.
109. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press; 1994.
110. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34(7):939-44.
111. Caselli RJ, Beach TG, Yaari R, Reiman EM. Alzheimer’s disease a century later. J Clin Psychiatry 2006;67(11):1784-800.
112. Barker WW, Luis CA, Kashuba A et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002;16(4):203-12.
113. Caviness JN. Myoclonus and neurodegenerative disease: what’s in a name? Parkinsonism Relat Disord 2003;9(4):185-92.
114. Attems J, Konig C, Huber M, Lintner F, Jellinger KA. Cause of death in demented and non-demented elderly inpatients; an autopsy study of 308 cases. J Alzheimer’s Dis 2005;8(1):57-62.
115. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98.
116. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol 1991;48(7):725-8.
117. Mungas D, Marshall SC, Weldon M, Haan M, Reed BR. Age and education correction of Mini-Mental State Examination for English and Spanish-speaking elderly. Neurology 1996;46(3):700-6.
118. Braaten AJ, Parsons TD, McCue R, Sellers A, Burns WJ. Neurocognitive differential diagnosis of dementing diseases: Alzheimer’s dementia, vascular dementia, frontotemporal dementia, and major depressive disorder. Int J Neurosci 2006;116(11):1271-93.
119. Crowell TA, Luis CA, Cox DE, Mullan M. Neuropsychological comparison of Alzheimer’s disease and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2007;23(2):120-5.
120. Diehl J, Monsch AU, Aebi C et al. Frontotemporal dementia, semantic dementia, and Alzheimer’s disease: the contribution of standard neuropsychological tests to differential diagnosis. J Geriatr Psychiatry Neurol 2005;18(1):39-44.
121. Rascovsky K, Salmon DP, Hansen LA, Thal LJ, Galasko D. Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer’s disease. Neuropsychology 2007;21(1):20-30.
122. Morris JC, Heyman A, Mohs RC et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39(9):1159-65.
123. Katzman R, Brown T, Fuld P et al. Validation of a short Orientation-Memory-Concentration Test of cognitive impairment. Am J Psychiatry 1983;140 (6):734-9.
124. Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Boston, MA: Veterans Administration Medical Center; 1978.
125. Berg L. Clinical Dementia Rating (CDR). Psychopharmacol Bull 1988;24(4):637-9.
126. Morris JC, Weintraub S, Chui HC et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20(4):210-16.
127. Wechsler D, Stone C. Manual: Wechsler Memory Scale. New York: Psychological Corporation; 1973.
128. Armitage S. An analysis of certain psychological tests used in evaluation of brain injury. Psych Mono 1946;60:1-48.
129. Wechsler D. Manual: Wechsler Adult Intelligence Scale. New York: Psychological Corporation; 1955.
130. Kaufer DI, Cummings JL, Ketchel P et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 2000; 12(2):233-9.
131. Pfeffer RI, Kurosaki TT, Harrah CH, Jr., Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37(3):323-9.
132. Sheikh J, Yesavage J. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In Brink T (ed.) Clinical Gerontology: A Guide to Assessment and Intervention. New York: Haworth Press; 1986:165-173.
133. Knopman DS, DeKosky ST, Cummings JL et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1143-53.
134. American Academy of Neurology. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter for diagnosis and evaluation of dementia. [Summary statement.] Neurology 1994;44(11):2203-6.
135. Mendez MF, Catanzaro P, Doss RC et al. Seizures in Alzheimer’s disease: clinicopathologic study. J Geriatr Psychiatry Neurol 1994;7(4):230-3.
136. Lozsadi DA, Larner AJ. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer’s disease. Dement Geriatr Cogn Disord 2006;22(2):121-4.
137. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 1999; 52(8):1555-62.
138. Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci 1998;158(2):134-40.
139. Gomez-Tortosa E, Gonzalo I, Fanjul S et al. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. Arch Neurol 2003;60(9):1218-22.
140. Sunderland T, Linker G, Mirza N et al. Decreased betaamyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003; 289(16):2094-103.
141. Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61(1):95-102.
142. Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5(3):228-34.
143. Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer’s disease: levels of betaamyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 2006;21(3):131-8.
144. Zakzanis KK, Graham SJ, Campbell Z. A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer’s type: a neuroimaging profile. Neuropsychol Rev 2003;13(1):1-18.
145. Yavuz BB, Ariogul S, Cankurtaran M et al. Hippocampal atrophy correlates with the severity of cognitive decline. Int Psychogeriatr 2006:19:767-77.
146. Laakso MP, Partanen K, Riekkinen P et al. Hippocampal volumes in Alzheimer’s disease, Parkinson’s disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996;46(3):678-81.
147. Frisoni GB, Laakso MP, Beltramello A et al. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer’s disease. Neurology 1999;52(1):91-100.
148. Nagy Z, Hindley NJ, Braak H et al. Relationship between clinical and radiological diagnostic criteria for Alzheimer’s disease and the extent of neuropathology as reflected by “stages”: a prospective study. Dement Geriatr Cogn Disord 1999;10(2):109-14.
149. van de Pol LA, Hensel A, Barkhof F et al. Hippocampal atrophy in Alzheimer disease: age matters. Neurology 2006;66(2):236-8.
150. Jack CR, Jr., Petersen RC, Xu YC et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52(7): 1397-403.
151. deToledo-Morrell L, Stoub TR, Bulgakova M et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004;25(9):1197-203.
152. Mattman A, Feldman H, Forster B et al. Regional Hm PAO SPECT and CT measurements in the diagnosis of Alzheimer’s disease. Can J Neurol Sci 1997;24(1):22-8.
153. Van Gool WA, Walstra GJ, Teunisse S et al. Diagnosing Alzheimer’s disease in elderly, mildly demented patients: the impact of routine single photon emission computed tomography. J Neurol 1995; 242(6):401-5.
154. Bonte FJ, Weiner MF, Bigio EH, White CL, III. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997;202(3):793-7.
155. Herholz K, Salmon E, Perani D et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17(1):302-16.
156. Hoffman JM, Welsh-Bohmer KA, Hanson M et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41(11):1920-8.
157. Chetelat G, Desgranges B, de la Sayette V et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 2003;60(8):1374-7.
158. Klunk WE, Engler H, Nordberg A et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 2004;55(3):306-19.
159. Shoghi-Jadid K, Small GW, Agdeppa ED et al. Localization of neurofibrillary tangles and betaamyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002; 10(1):24-35.
160. Kung MP, Hou C, Zhuang ZP, Skovronsky D, Kung HF. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer’s disease. Brain Res 2004; 1025(1-2):98-105.
161. Engler H, Forsberg A, Almkvist O et al. Two-year follow-up of amyloid deposition in patients with Alzheimer’s disease. Brain 2006;129(Pt 11):2856-66.
162. Small GW, Kepe V, Barrio JR. Seeing is believing: neuroimaging adds to our understanding of cerebral pathology. Curr Opin Psychiatry 2006;19(6):564-9.
163. Lockhart A. Imaging Alzheimer’s disease pathology: one target, many ligands. Drug Discov Today 2006; 11(23-24):1093-9.
164. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;1: CD005593.
165. Bullock R, Touchon J, Bergman H et al. Rivastigmine and donepezil treatment in moderate to moderatelysevere Alzheimer’s disease over a 2-year period. Curr Med Res Opin 2005;21(8):1317-27.
166. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer’s disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 2005;59(7):817-22.
167. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999;318(7184):633-8.
168. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebocontrolled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54(12):2261-8.
169. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidencebased review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56(9):1154-66.
170. Kmietowicz Z. NICE proposes to withdraw Alzheimer’s drugs from NHS. BMJ 2005;330 (7490):495.
171. Harkany T, Abraham I, Timmerman W et al. Betaamyloid neurotoxicity is mediated by a glutamatetriggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000;12(8):2735-45.
172. Topper R, Gehrmann J, Banati R et al. Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury. Acta Neuropathol (Berl) 1995;89(1):23-8.
173. Couratier P, Lesort M, Sindou P et al. Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity. Mol Chem Neuropathol 1996;27(3):259-73.
174. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003;2(8):503-5.
175. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291(3): 317-24.
176. Lyketsos CG, Sheppard JM, Steele CD et al. Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer’s disease: initial results from the Depression in Alzheimer’s Disease Study. Am J Psychiatry 2000;157(10):1686-9.
177. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer’s disease. Psychosomatics 1997;38(3):246-52.
178. Alexopoulos GS, Jeste DV, Chung H et al. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005; (Spec No):6-22.
179. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293(5):596-608.
180. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006;355 (15):1525-38.
181. Wang PS, Schneeweiss S, Avorn J et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353(22):2335-41.
182. Beier MT. Treatment strategies for the behavioral symptoms of Alzheimer’s disease: focus on early pharmacologic intervention. Pharmacotherapy 2007; 27(3):399-411.
183. Dubinsky RM, Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer’s disease (an evidencebased review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;54(12):2205-11.
184. Wang C, Kosinski C, Schwartzberg J. Physician’s Guide to Assessing and Counseling Older Drivers. Washington, DC: National Highway Traffic Safety Administration; 2003.
185. Friedland RP, Koss E, Kumar A et al. Motor vehicle crashes in dementia of the Alzheimer type. Ann Neurol 1988;24(6):782-6.
186. Carr DB, Duchek J, Morris JC. Characteristics of motor vehicle crashes of drivers with dementia of the Alzheimer type. J Am Geriatr Soc 2000;48(1):18-22.
187. Molnar FJ, Patel A, Marshall SC, Man-Son-Hing M, Wilson KG. Clinical utility of office-based cognitive predictors of fitness to drive in persons with dementia: a systematic review. J Am Geriatr Soc 2006;54 (12):1809-24.
188. Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer’s disease. Science 2006;314(5800):781-4.
189. Chang WP, Koelsch G, Wong S et al. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 2004;89(6):1409-16.
190. Etcheberrigaray R, Tan M, Dewachter I et al. Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice. Proc Natl Acad Sci USA 2004;101(30):11141-6.
191. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16(5):599-606.
192. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer’s disease. Nat Rev Immunol 2006;6(5):404-16.
193. Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61(1):46-54.
194. Geerts H. NC-531 (Neurochem). Curr Opin Investig Drugs 2004;5(1):95-100.
195. Crouch PJ, Barnham KJ, Bush AI, White AR. Therapeutic treatments for Alzheimer’s disease based on metal bioavailability. Drug News Perspect 2006;19 (8):469-74.
196. Engel T, Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006;99(6):1445-55.
197. Delanty N, Vaughan C. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1998;51(2):652.
198. Szekely CA, Thorne JE, Zandi PP et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review. Neuroepidemiology 2004;23(4):159-69.
199. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. Lancet Neurol 2002;1(5):279-84.
200. Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112(3):440-9.
201. Tang MX, Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348(9025):429-32.
202. Henderson VW, Paganini-Hill A, Miller BL et al. Estrogen for Alzheimer’s disease in women: randomized, double-blind, placebo-controlled trial. Neurology 2000;54(2):295-301.
203. Engelhart MJ, Geerlings MI, Ruitenberg A et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287(24):3223-9.
204. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336(17):1216-22.
205. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293(11):1338-47.
206. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356(9242):1627-31.
207. Yang F, Lim GP, Begum AN et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280(7):5892-901.
208. Reddy PH, McWeeney S. Mapping cellular transcriptosomes in autopsied Alzheimer’s disease subjects and relevant animal models. Neurobiol Aging 2006;27(8):1060-77.
209. Davidsson P, Sjogren M. Proteome studies of CSF in AD patients. Mech Ageing Dev 2006;127(2):133-7.
210. Hye A, Lynham S, Thambisetty M et al. Proteomebased plasma biomarkers for Alzheimer’s disease. Brain 2006;129(Pt 11):3042-50.
211. Mueller SG, Weiner MW, Thal LJ et al. The Alzheimer’s disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15(4):869-77, xi-xii.
212. Lopponen M, Raiha I, Isoaho R, Vahlberg T, Kivela SL. Diagnosing cognitive impairment and dementia in primary health care: a more active approach is needed. Age Ageing 2003;32(6):606-12.
213. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann InternMed 1995; 122(6):422-9.
214. Svansdottir HB, Snaedal J. Music therapy in moderate and severe dementia of Alzheimer’s type: a case-control study. Int Psychogeriatr 2006;18(4):613-21.
215. Rolland Y, Pillard F, Klapouszczak A et al. Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial. J Am Geriatr Soc 2007;55(2):158-65.